S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Adamis Pharmaceuticals Stock Forecast, Price & News

-0.07 (-8.54%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.98 million shs
Average Volume
10.03 million shs
Market Capitalization
$111.66 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adamis Pharmaceuticals logo

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.


Adamis Pharmaceuticals (ADMP) to Release Earnings on Monday
November 20, 2021 |  americanbankingnews.com
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 |  finance.yahoo.com
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
September 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$16.53 million
Book Value
$0.03 per share


Net Income
$-49.39 million
Net Margins
Pretax Margin




Free Float
Market Cap
$111.66 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.11 out of 5 stars

Medical Sector

1221st out of 1,392 stocks

Pharmaceutical Preparations Industry

583rd out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals
or view top-rated stocks.

How has Adamis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMP shares have increased by 86.2% and is now trading at $0.75.
View which stocks have been most impacted by COVID-19

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a increase in short interest in October. As of October 29th, there was short interest totaling 14,160,000 shares, an increase of 47.3% from the October 14th total of 9,610,000 shares. Based on an average daily volume of 6,180,000 shares, the short-interest ratio is currently 2.3 days.
View Adamis Pharmaceuticals' Short Interest

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Adamis Pharmaceuticals

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its quarterly earnings results on Monday, November, 22nd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.03. The specialty pharmaceutical company earned $0.76 million during the quarter. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 126.38% and a negative net margin of 458.77%.
View Adamis Pharmaceuticals' earnings history

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:
  • Dennis J. Carlo, President, Chief Executive Officer & Director
  • Karen K. Daniels, Vice President-Operations
  • David C. Benedicto, Chief Financial & Accounting Officer
  • Ronald B. Moss, Chief Medical Officer
  • Thomas H. Moll, Vice President-Research

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.90%), Millennium Management LLC (0.37%), Atom Investors LP (0.04%), Citadel Advisors LLC (0.00%), HighTower Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends for Adamis Pharmaceuticals

Which institutional investors are selling Adamis Pharmaceuticals stock?

ADMP stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
View insider buying and selling activity for Adamis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Adamis Pharmaceuticals stock?

ADMP stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Atom Investors LP, Geode Capital Management LLC, and HighTower Advisors LLC.
View insider buying and selling activity for Adamis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.75.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $111.66 million and generates $16.53 million in revenue each year.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 130 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.